ReviewFrontiers in immunology2022
Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.Journal of neurology · 2024Pooled it
- Movement disorders in cell surface antibody mediated autoimmune encephalitis: a meta-analysis.Frontiers in neurology · 2023Pooled it
- Suspected encephalitis in adults.Practical neurology · 2026Review
- Article
- Clinical features, outcome and HLA subtypes in Eastern patients with anti-IgLON5 disease: a multicenter study.Orphanet journal of rare diseases · 2026Article
- IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity.Science advances · 2026Article
- A patient with anti-IgLON5 disease associated with cerebral hemorrhage, multiple ischemic strokes, and kidney failure: case report.Journal of neurology · 2026Article
- Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.Antibodies (Basel, Switzerland) · 2026Review
- Facio-Brachial Dystonic Seizures as an Atypical Presentation of Anti-IgLON5 Disease.Journal of central nervous system disease · 2026Article
- Progressive Supranuclear Palsy With Post-traumatic Frontal Lobe Damage Mimicking Anti-IgLON5 Antibody Disease.Cureus · 2025Article
- Article
- A Distinctive Inspiratory Noise in IgLON5-Antibody Disease.JAMA neurology · 2025Article
- Homer-3 antibody in autoimmune cerebellar syndromes: a potentially treatable mimic of MSA-C - A review.Frontiers in immunology · 2025Review
- A fatal familial insomnia patient initially misdiagnosed as Alzheimer's disease: a case report.BMC neurology · 2024Article
- Further insights into anti-IgLON5 disease: a case with complex clinical presentation.BMC neurology · 2024Article
- Emerging Biomarkers for the Early Detection of Autoimmune Encephalitis: A Narrative Review.Cureus · 2024Review
- IgLON5-IgG: Innocent Bystander or Perpetrator?International journal of molecular sciences · 2024Review
- Atypical brain MRI findings in a patient with treatment responsive anti-IgLON5 disease.Radiology case reports · 2024Article
- Diagnosis and Management of Progressive Corticobasal Syndrome.Current treatment options in neurology · 2024Article
- An Autopsy-proven Case-based Review of Autoimmune Encephalitis.Experimental neurobiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-IgLON5 disease is a relatively new neurological entity with the first cases reported in 2014. So far, less than 70 articles on this topic have been published. Due to its unspecific symptomatology, diverse progression, novelty and ambiguous character, it remains a difficulty for both clinical practitioners and scientists. The aim of this review is to summarize the current knowledge concerning anti-IgLON5 disease; mechanisms underlying its cause, symptomatology, clinical progression, differential diagnosis and treatment, which could be helpful in clinical practice and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.